BR0213410A - Usos farmacêuticos de bisfosfonatos - Google Patents
Usos farmacêuticos de bisfosfonatosInfo
- Publication number
- BR0213410A BR0213410A BR0213410-1A BR0213410A BR0213410A BR 0213410 A BR0213410 A BR 0213410A BR 0213410 A BR0213410 A BR 0213410A BR 0213410 A BR0213410 A BR 0213410A
- Authority
- BR
- Brazil
- Prior art keywords
- effective amount
- bisphosphonates
- pharmaceutical uses
- bisphosphonate
- taxol
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title abstract 4
- 150000004663 bisphosphonates Chemical class 0.000 title abstract 4
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 229940111134 coxibs Drugs 0.000 abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000003211 malignant effect Effects 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34592101P | 2001-10-19 | 2001-10-19 | |
| PCT/EP2002/011696 WO2003035081A1 (en) | 2001-10-19 | 2002-10-18 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213410A true BR0213410A (pt) | 2004-11-03 |
Family
ID=23357099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213410-1A BR0213410A (pt) | 2001-10-19 | 2002-10-18 | Usos farmacêuticos de bisfosfonatos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7345088B2 (enExample) |
| EP (1) | EP1443942B1 (enExample) |
| JP (1) | JP2005506371A (enExample) |
| KR (1) | KR20040066103A (enExample) |
| CN (1) | CN100372539C (enExample) |
| AT (1) | ATE382347T1 (enExample) |
| AU (1) | AU2002363089B2 (enExample) |
| BR (1) | BR0213410A (enExample) |
| CA (1) | CA2461085A1 (enExample) |
| CO (1) | CO5570672A2 (enExample) |
| DE (1) | DE60224429T2 (enExample) |
| DK (1) | DK1443942T3 (enExample) |
| EC (1) | ECSP045054A (enExample) |
| ES (1) | ES2301710T3 (enExample) |
| HU (1) | HUP0402061A3 (enExample) |
| IL (2) | IL161090A0 (enExample) |
| MX (1) | MXPA04003671A (enExample) |
| NO (1) | NO20042056L (enExample) |
| NZ (1) | NZ532282A (enExample) |
| PL (1) | PL367707A1 (enExample) |
| PT (1) | PT1443942E (enExample) |
| RU (1) | RU2317819C2 (enExample) |
| SI (1) | SI1443942T1 (enExample) |
| WO (1) | WO2003035081A1 (enExample) |
| ZA (1) | ZA200402089B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0204756D0 (en) * | 2002-02-28 | 2002-04-17 | Novartis Ag | Organic compounds |
| GB0328040D0 (en) * | 2003-12-03 | 2004-01-07 | Coleman Robert E | Pharmaceutical uses of bisphosphonates |
| FR2939314A1 (fr) * | 2008-12-04 | 2010-06-11 | Univ Victor Segalen Bordeaux 2 | Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| KR101813728B1 (ko) * | 2009-07-31 | 2017-12-29 | 그뤼넨탈 게엠베하 | 결정화 방법 및 생체이용률 |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187130A (zh) * | 1995-06-06 | 1998-07-08 | 麦克公司 | 用二磷酸盐预防与免疫抑制疗法有关的骨损失 |
| WO2000038715A2 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of an integrin antagonist and radiation in the treatment of neoplasia |
| EP1253921A4 (en) * | 2000-01-28 | 2004-10-13 | Merck & Co Inc | TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS |
-
2002
- 2002-10-18 HU HU0402061A patent/HUP0402061A3/hu unknown
- 2002-10-18 CA CA002461085A patent/CA2461085A1/en not_active Abandoned
- 2002-10-18 CN CNB028207823A patent/CN100372539C/zh not_active Expired - Fee Related
- 2002-10-18 PL PL02367707A patent/PL367707A1/xx not_active Application Discontinuation
- 2002-10-18 EP EP02801899A patent/EP1443942B1/en not_active Expired - Lifetime
- 2002-10-18 PT PT02801899T patent/PT1443942E/pt unknown
- 2002-10-18 RU RU2004115337/15A patent/RU2317819C2/ru not_active IP Right Cessation
- 2002-10-18 NZ NZ532282A patent/NZ532282A/en unknown
- 2002-10-18 JP JP2003537648A patent/JP2005506371A/ja active Pending
- 2002-10-18 AU AU2002363089A patent/AU2002363089B2/en not_active Ceased
- 2002-10-18 US US10/493,042 patent/US7345088B2/en not_active Expired - Fee Related
- 2002-10-18 DE DE60224429T patent/DE60224429T2/de not_active Expired - Fee Related
- 2002-10-18 MX MXPA04003671A patent/MXPA04003671A/es active IP Right Grant
- 2002-10-18 IL IL16109002A patent/IL161090A0/xx unknown
- 2002-10-18 SI SI200230676T patent/SI1443942T1/sl unknown
- 2002-10-18 AT AT02801899T patent/ATE382347T1/de not_active IP Right Cessation
- 2002-10-18 DK DK02801899T patent/DK1443942T3/da active
- 2002-10-18 KR KR10-2004-7005630A patent/KR20040066103A/ko not_active Ceased
- 2002-10-18 ES ES02801899T patent/ES2301710T3/es not_active Expired - Lifetime
- 2002-10-18 WO PCT/EP2002/011696 patent/WO2003035081A1/en not_active Ceased
- 2002-10-18 BR BR0213410-1A patent/BR0213410A/pt not_active IP Right Cessation
-
2004
- 2004-03-16 ZA ZA200402089A patent/ZA200402089B/en unknown
- 2004-03-25 IL IL161090A patent/IL161090A/en not_active IP Right Cessation
- 2004-04-08 EC EC2004005054A patent/ECSP045054A/es unknown
- 2004-04-15 CO CO04034537A patent/CO5570672A2/es not_active Application Discontinuation
- 2004-05-18 NO NO20042056A patent/NO20042056L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL161090A0 (en) | 2004-08-31 |
| PT1443942E (pt) | 2008-04-07 |
| SI1443942T1 (sl) | 2008-08-31 |
| ECSP045054A (es) | 2004-05-28 |
| HUP0402061A3 (en) | 2007-05-29 |
| NZ532282A (en) | 2006-02-24 |
| DK1443942T3 (da) | 2008-05-19 |
| CN100372539C (zh) | 2008-03-05 |
| WO2003035081A1 (en) | 2003-05-01 |
| HK1080733A1 (en) | 2006-05-04 |
| CO5570672A2 (es) | 2005-10-31 |
| HUP0402061A2 (hu) | 2005-02-28 |
| NO20042056L (no) | 2004-05-18 |
| RU2317819C2 (ru) | 2008-02-27 |
| CN1703226A (zh) | 2005-11-30 |
| KR20040066103A (ko) | 2004-07-23 |
| DE60224429D1 (de) | 2008-02-14 |
| DE60224429T2 (de) | 2008-12-18 |
| ES2301710T3 (es) | 2008-07-01 |
| MXPA04003671A (es) | 2005-06-20 |
| IL161090A (en) | 2010-04-15 |
| ZA200402089B (en) | 2005-06-22 |
| CA2461085A1 (en) | 2003-05-01 |
| ATE382347T1 (de) | 2008-01-15 |
| PL367707A1 (en) | 2005-03-07 |
| AU2002363089B2 (en) | 2006-02-16 |
| EP1443942B1 (en) | 2008-01-02 |
| EP1443942A1 (en) | 2004-08-11 |
| US20050014726A1 (en) | 2005-01-20 |
| US7345088B2 (en) | 2008-03-18 |
| RU2004115337A (ru) | 2005-04-20 |
| JP2005506371A (ja) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| BR0209365A (pt) | Usos farmacêuticos de bisfosfonatos | |
| BRPI0418029A (pt) | formulação de anticorpos cd40 e métodos | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BRPI0308663B8 (pt) | uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas | |
| BR0115696A (pt) | Uso de bisfosfonatos para tratamento de dor | |
| BR0314854A (pt) | Dispositivo médico para difusão de medicamentos | |
| BR0013219A (pt) | Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto | |
| BR9815442A (pt) | Liberação terapêutica dirigida de compostos de vitamina d | |
| BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
| AR052921A1 (es) | Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica | |
| BR0110420A (pt) | Agonistas muscarìnicos | |
| ES2164040T1 (es) | Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos. | |
| BR0010531A (pt) | Composições e usos de et743 para tratamento de câncer | |
| BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
| BR0009524A (pt) | Uso de um composto, e, composição farmacêutica ou veterinaria | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| BR9814214A (pt) | Composição com ácido azeláico | |
| BR0314081A (pt) | Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase | |
| BR0213181A (pt) | Combinações de inibidor de cox-2 | |
| BR0010515A (pt) | Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica | |
| BR0313081A (pt) | Combinação de um inibidor de aromatase com um bisfosfanato | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| ES2167385T3 (es) | Medicamentos de accion antihiperglicemica. | |
| PL367707A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |